Indo and Akira Takahashi L-Dopa was administered to 122 patients with Parkinson's disease over a time period oup to 14 years. The results were summarized below. 1) The akinesia and postural instability scores were significantly improved up to the 9th year.
the effect of L-dopa becomes gradually attenuated as the duration of treatment increases~. For example, Rinne et al. reported that a complete reversion to the pretreatment condition occurred 7 years after initiation of treatment and Rajput et al. also reported that the same occurred 5 years after initiation of treatment. In Japan, we know of few published reports^on this subject.
There are opposite views on the opportune time of initiation of L-dopa therapy from the standpoint of long-term prognosis:
one school of thought claims that the initiation of L-dopa therapy should be postponed until the degree of disability is so advanced as to interfere with activities of daily living5'7' . The other school says that Ldopa therapy should be initiated at the earliest possible stage9' . The question remains to be answered yet.
The present study was conducted to investigate the time course of the clinical effect of L-dopa in 122 patients on the therapy for a varying period of time up to 14 years and also to determine which is more appropriate, the early initiation of L-dopa therapy or the postponement of L-dopa therapy up to the time when functional disturbances have progressed so muchas to cause difficulties in daily life.
SUBJECTS AND METHODS
The study was conducted in 122 patients with Parkinson's disease. They were 54 men and 68 women, aged 39 to 78 years (mean ± S.E., 59. 3 stage IV/V in 49. The interval between the first onset of disease and the initiation of L-dopa therapy was 24.58 ± 27.82 months in stage I/II patients, 48.6 ± 33.90 months in stage III patients, 82.39 ± 69.65 months in stage IV/V patients.
Ldopa (alone or in combination with a peripheral decarboxylase inhibitor) was administered to the above patients in stepwise-increasing doses, and weighting therapeutic effects with side effects, the daily dose of L-dopa on the single agent basis was set at 3.0 g or less. In combination therapy using L-dopa and a peripheral decarboxylase inhibitor, the actual dose of L-dopa was multiplied by 5 for calculation of the single agent equivalent. Patients treated concurrently with L-threo-DOPS or bromocriptine were excluded from the present study.
In evaluating the therapeutic effect of L-dopa, and P (3 items): forward, sideway and backward.
As to the evaluation method, PS and four major signs of the disease were all evaluated on the 4-point scale of severe = 3, moderate = 2, mild = 1, and none = 0. Thus, the maximumscore was 15 (3) Time course ofA score ( Fig. 1-A 2) Study on the opportune time of initiation of Ldopa therapy (Fig. 4) The chronology of Parkinson's disease shows that unless treated the disease progresses from Yahr stage I/II to Yahr stage III or IV/V in afew years. For an accurate comparison of changes due to L-dopa therapy among these three groups, it is important to take into account the time interval between the onset of the disease and the initiation of L-dopa therapy.
Concerning argued that progression of the disease results in so few remaining nigrostriatal dojpaminergic neurons that a sufficient amountof dopamineto stimulate the striatal dopamine receptors cannot be produced. As to the extent of declining efficacy, Rajput et al5^reported that the degree of improvement reaches a peak at 6 months after initiation of the therapy but the effect of the therapy begins to decline in the second year and while a significant 
